Loop Diuretic (Furosemide or Torsemide)
In this 76-year-old male with stage 4 CKD (GFR 15 mL/min) and persistent hypertension on diltiazem, the safest antihypertensive to add is a loop diuretic, specifically furosemide or torsemide. Additionally, you should strongly consider discontinuing the diltiazem entirely and transitioning to a more appropriate regimen for his level of renal impairment.
Why Loop Diuretics Are the Answer
With a GFR of 15 mL/min, this patient has severe renal impairment where thiazide diuretics lose effectiveness. Loop diuretics are essential for volume control and blood pressure management when creatinine clearance falls below 30 mL/min 1. The guidelines are explicit: in patients with severe renal impairment, loop diuretics should be used for volume control 1.
The BP of 142/60 suggests volume expansion contributing to systolic hypertension—a common scenario in advanced CKD. Loop diuretics directly address this pathophysiology 2. Studies show that patients with resistant hypertension frequently have occult volume expansion, and increased diuresis significantly improves BP control 2.
Specific Recommendations:
- Furosemide: Requires twice-daily dosing due to short duration of action, but widely available and familiar
- Torsemide: Preferred option with longer duration allowing once-daily dosing and potentially better bioavailability 2
The Diltiazem Problem
You should seriously consider stopping diltiazem in this patient. Here's why this matters for morbidity and mortality:
Nondihydropyridine calcium channel blockers (diltiazem and verapamil) are specifically contraindicated in patients with heart failure due to negative inotropic effects 1. While we don't have explicit heart failure documentation here, the combination of advanced CKD, hypertension, and age puts this patient at extremely high risk. The guidelines state these agents "should be avoided" in this context 1.
Building the Optimal Regimen
After adding (or switching to) a loop diuretic, the evidence-based approach for CKD patients includes:
ACE inhibitor or ARB - First-line for renal protection, especially if any proteinuria exists (which is likely with GFR 15) 3, 4, 5
- Monitor potassium and creatinine closely
- Accept up to 30% creatinine rise if stable
Dihydropyridine calcium channel blocker (amlodipine or felodipine) - Can replace diltiazem if you want to maintain CCB therapy 1
- Unlike diltiazem, these are safe and effective in CKD
- Amlodipine specifically shown safe even in severe dysfunction 1
Loop diuretic (as discussed above)
Critical Monitoring Points
Hyperkalemia risk: With GFR 15, potassium management becomes paramount. Check potassium within 1-2 weeks of any medication change 5. Consider dietary potassium restriction and potentially a potassium binder if needed to allow continuation of renin-angiotensin system blockade.
Blood pressure targets: For this patient, target BP <130/80 mmHg 3, 4. However, note his diastolic BP is already 60 mmHg. The guidelines specifically warn about lowering DBP below 60 mmHg in patients over age 60, as this can worsen outcomes 1. Focus on systolic control while monitoring for symptoms of hypoperfusion.
Volume status: The wide pulse pressure (142/60 = 82 mmHg) suggests arterial stiffness and possible volume overload. Assess for edema, jugular venous distension, and orthopnea. Adjust loop diuretic dose based on volume status and BP response.
Common Pitfalls to Avoid
- Don't use thiazide diuretics - They're ineffective at GFR <30 mL/min 1, 2, 1
- Don't combine ACE inhibitor + ARB - This increases cardiovascular and renal risk without benefit 6, 5
- Don't underdose the loop diuretic - Patients with CKD often need higher doses; furosemide 40-80 mg twice daily or torsemide 20-100 mg daily may be required 2
- Don't ignore the need for nephrology referral - At GFR 15, this patient needs specialist co-management for impending dialysis planning
Alternative Consideration: Mineralocorticoid Receptor Antagonist
If loop diuretic alone doesn't achieve BP control, spironolactone 25 mg daily is highly effective in resistant hypertension and provides additional renal protection 2, 7, 8. However, at GFR 15, hyperkalemia risk is substantial. This requires:
- Baseline potassium <5.0 mEq/L
- Weekly potassium monitoring initially
- Patient education about dietary potassium restriction
- Availability of potassium binders if needed
The evidence shows spironolactone reduces BP by 6.6-8.7 mmHg in resistant hypertension 7, but safety in severe CKD requires vigilant monitoring.